文献速递妇产影像技术与安全US

超声分子成像联合VEGFR2靶向微泡评估子宫内膜损伤后宫腔粘连及监测治疗效果

Ultrasound Molecular Imaging With VEGFR2-Targeted Microbubbles to Evaluate Intrauterine Adhesion After Endometrial Injury and Monitor the Therapeutic Effects.
PubMed 文献 · J Ultrasound Med · 2025-05-05

研究构建VEGFR2靶向微泡(MBVEGFR2),在大鼠化学损伤IUA模型中行超声分子成像,模型组子宫组织对比信号强度62.5±17.9 dB高于正常组33.5±12.5 dB(P<.05),免疫组化显示模型组VEGFR2与α-SMA表达高于标准组(P<.05)。结论认为基于MBVEGFR2的超声分子成像可评估子宫血管内皮VEGFR2表达水平,为子宫内膜损伤后宫腔粘连的早期诊断与治疗监测提供潜在途径。

要点

  • 模型组子宫组织MBVEGFR2对比超声信号强度62.5±17.9 dB,正常组33.5±12.5 dB,差异有统计学意义(P<.05)。
  • 免疫组化显示模型组子宫组织VEGFR2与α-SMA表达高于标准组(P<.05),提示对比信号可反映VEGFR2分子表达水平。
  • MBVEGFR2平均粒径2309.6±234.3 nm,平均zeta电位-16.9±0.15 mV,分散系数小于0.4。

核心结论

  • 基于MBVEGFR2的超声分子成像可评估子宫血管内皮细胞VEGFR2表达水平,为子宫内膜损伤后宫腔粘连的早期诊断与治疗监测提供潜在途径。

研究设计与样本

  • 动物实验研究,通过「生物素-亲和素-生物素」桥接技术构建MBVEGFR2,经化学损伤构建大鼠IUA模型,造模14天后向标准组与模型组大鼠注射MBCon与MBVEGFR2对比剂行超声分子成像,以差异化靶向增强(dTE)归一化体内超声信号变化,并用免疫组化检测两组子宫组织VEGFR2与α-SMA表达水平。

关键影像表现/征象

  • 注射靶向MBVEGFR2后,模型组子宫组织对比超声信号强度62.5±17.9 dB高于正常组33.5±12.5 dB,差异有统计学意义(P<.05)。
  • 免疫组化显示模型组子宫组织VEGFR2与α-SMA表达高于标准组(P<.05)。

诊断标准与关键数值

  • MBVEGFR2平均粒径2309.6±234.3 nm,平均zeta电位-16.9±0.15 mV,分散系数小于0.4。
  • 以差异化靶向增强(dTE)归一化体内超声信号变化。

临床应用与阅片要点

  • 作者认为基于MBVEGFR2的超声分子成像可用于评估子宫血管内皮细胞VEGFR2表达水平,为子宫内膜损伤后宫腔粘连的早期诊断与治疗监测提供潜在途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the severity of intrauterine adhesion (IUA) after endometrial injury via ultrasound molecular imaging (USMI) of vascular endothelial growth factor receptor 2 (VEGFR2) expression on the uterine endothelium.

METHODS: MBVEGFR2 was constructed via "biotin-avidin-biotin" bridging technology. A rat IUA animal model was constructed via chemical injury. Fourteen days after the model was constructed, MBCon and MBVEGFR2 contrast agents were injected into the standard group and the model group of rats, and simultaneous ultrasound molecular imaging was carried out and ultrasound molecular imaging was performed and the changes in ultrasound signals in vivo were normalized to differential targeted enhancement (dTE). In addition, immunohistochemistry was used to detect the expression levels of VEGFR2 and α-SMA in the uterine tissues of the rats in both groups.

RESULTS: Targeted-VEGFR2 microbubble (MBVEGFR2) was successfully constructed, the average particle size of the targeted VEGFR2 microbubble contrast agent was 2309.6 ± 234.3 nm, with the average zeta potential -16.9 ± 0.15 mV and the dispersity coefficient less than 0.4. In addition, its essential performance and biosafety were examined, which revealed that the MBVEGFR2 contrast agent had an appropriate size, stable imaging performance, good target adhesion, and good biocompatibility. In vivo, ultrasound imaging results revealed that after the injection of the targeted MBVEGFR2, the contrast ultrasound signal intensity of uterine tissues in the model group (62.5 ± 17.9 dB) was higher than in the normal group (33.5 ± 12.5 dB), and the difference was statistically significant (P < .05). The immunohistochemistry results revealed that the expression of VEGFR2 and α-SMA in the uterine tissue of the model group was greater than that in the standard group (P < .05), further indicating that the signal intensity of the MBVEGFR2 contrast agent can reflect the expression level of VEGFR2 molecules.

CONCLUSIONS: Ultrasound molecular imaging based on MBVEGFR2 can be used to evaluate the expression level of VEGFR2 in uterine vascular endothelial cells. This provides a potential approach for the early diagnosis and treatment monitoring of intrauterine adhesions after endometrial injury.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Hou L, Guo Z, Liu S, et al. Ultrasound Molecular Imaging With VEGFR2-Targeted Microbubbles to Evaluate Intrauterine Adhesion After Endometrial Injury and Monitor the Therapeutic Effects. J Ultrasound Med. 2025. PMID: 40323121. doi:10.1002/jum.16710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。